Use of platelet and erythroid growth factors during induction chemotherapy for acute lymphoblastic leukaemia in a Jehovah's Witness

Nivedita Arora, Arjun Gupta, Hsiao-Ching Li, Navid Sadeghi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We present a 21-year-old woman diagnosed with Philadelphia (Ph) chromosome-like CD20 positive B-cell acute lymphoblastic leukaemia (ALL). She was a Jehovah's Witness (JW) and declined all blood product transfusion support. She was initiated on the CALGB 10403 chemotherapy protocol for her ALL. She received darbepoetin alfa and romiplostim as supportive therapies for her disease/chemotherapy-associated anaemia and thrombocytopaenia. A complete remission was achieved with negative minimal residual disease and she remains in remission 18 months after diagnosis. This case report describes the successful treatment of an adult JW with Ph-like CD20 +B cell ALL, in the absence of blood product transfusions, using growth factor support.

Original languageEnglish (US)
Article numbere226497
JournalBMJ Case Reports
Volume11
Issue number1
DOIs
StatePublished - Dec 1 2018

Fingerprint

Jehovah's Witnesses
Induction Chemotherapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Intercellular Signaling Peptides and Proteins
Blood Platelets
Blood Transfusion
B-Lymphocytes
Drug Therapy
Philadelphia Chromosome
Residual Neoplasm
Anemia
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Use of platelet and erythroid growth factors during induction chemotherapy for acute lymphoblastic leukaemia in a Jehovah's Witness. / Arora, Nivedita; Gupta, Arjun; Li, Hsiao-Ching; Sadeghi, Navid.

In: BMJ Case Reports, Vol. 11, No. 1, e226497, 01.12.2018.

Research output: Contribution to journalArticle

@article{c7f7e93aecf84751a8070752d613abdf,
title = "Use of platelet and erythroid growth factors during induction chemotherapy for acute lymphoblastic leukaemia in a Jehovah's Witness",
abstract = "We present a 21-year-old woman diagnosed with Philadelphia (Ph) chromosome-like CD20 positive B-cell acute lymphoblastic leukaemia (ALL). She was a Jehovah's Witness (JW) and declined all blood product transfusion support. She was initiated on the CALGB 10403 chemotherapy protocol for her ALL. She received darbepoetin alfa and romiplostim as supportive therapies for her disease/chemotherapy-associated anaemia and thrombocytopaenia. A complete remission was achieved with negative minimal residual disease and she remains in remission 18 months after diagnosis. This case report describes the successful treatment of an adult JW with Ph-like CD20 +B cell ALL, in the absence of blood product transfusions, using growth factor support.",
author = "Nivedita Arora and Arjun Gupta and Hsiao-Ching Li and Navid Sadeghi",
year = "2018",
month = "12",
day = "1",
doi = "10.1136/bcr-2018-226497",
language = "English (US)",
volume = "11",
journal = "BMJ Case Reports",
issn = "1757-790X",
publisher = "BMJ Publishing Group",
number = "1",

}

TY - JOUR

T1 - Use of platelet and erythroid growth factors during induction chemotherapy for acute lymphoblastic leukaemia in a Jehovah's Witness

AU - Arora, Nivedita

AU - Gupta, Arjun

AU - Li, Hsiao-Ching

AU - Sadeghi, Navid

PY - 2018/12/1

Y1 - 2018/12/1

N2 - We present a 21-year-old woman diagnosed with Philadelphia (Ph) chromosome-like CD20 positive B-cell acute lymphoblastic leukaemia (ALL). She was a Jehovah's Witness (JW) and declined all blood product transfusion support. She was initiated on the CALGB 10403 chemotherapy protocol for her ALL. She received darbepoetin alfa and romiplostim as supportive therapies for her disease/chemotherapy-associated anaemia and thrombocytopaenia. A complete remission was achieved with negative minimal residual disease and she remains in remission 18 months after diagnosis. This case report describes the successful treatment of an adult JW with Ph-like CD20 +B cell ALL, in the absence of blood product transfusions, using growth factor support.

AB - We present a 21-year-old woman diagnosed with Philadelphia (Ph) chromosome-like CD20 positive B-cell acute lymphoblastic leukaemia (ALL). She was a Jehovah's Witness (JW) and declined all blood product transfusion support. She was initiated on the CALGB 10403 chemotherapy protocol for her ALL. She received darbepoetin alfa and romiplostim as supportive therapies for her disease/chemotherapy-associated anaemia and thrombocytopaenia. A complete remission was achieved with negative minimal residual disease and she remains in remission 18 months after diagnosis. This case report describes the successful treatment of an adult JW with Ph-like CD20 +B cell ALL, in the absence of blood product transfusions, using growth factor support.

UR - http://www.scopus.com/inward/record.url?scp=85058393247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058393247&partnerID=8YFLogxK

U2 - 10.1136/bcr-2018-226497

DO - 10.1136/bcr-2018-226497

M3 - Article

C2 - 30567199

AN - SCOPUS:85058393247

VL - 11

JO - BMJ Case Reports

JF - BMJ Case Reports

SN - 1757-790X

IS - 1

M1 - e226497

ER -